The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review


Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Retreatment


High impact information on Retreatment


Chemical compound and disease context of Retreatment


Biological context of Retreatment

  • Analysis of variance showed that significant haze after the first PRK was the most important predictor of a poor outcome after retreatment, other factors being high original myopia, marked regression, and loss of best-corrected visual acuity [15].
  • The effect of treatment dose on the kinetics of MeCCNU resistance development was also studied in a retreatment regimen where the tumours were allowed to regrow and then transplanted into fresh hosts for the next treatment [16].
  • We report the case of a man with a formidable body burden of lead (Pb) and depleted iron stores who was given iron intramuscularly during a defined period of long-term retreatment with DMSA [17].
  • AIM: To describe the role of calcium hydroxide in infection control during complex endodontic retreatment [18].
  • This is especially true if she decides to become pregnant, needs retreatment with a GnRH agonist or will be going through natural menopause in the near future; all can cause further bone loss [19].

Anatomical context of Retreatment

  • In an attempt to improve the survival of children with a late bone marrow (BM) relapse (ie, occurring greater than 6 months after cessation of primary therapy), the Pediatric Oncology Group designed a randomized study to compare the efficacy of doxorubicin/prednisone and cytarabine/teniposide in a multidrug retreatment chemotherapy program [20].
  • In case of an objective response, retreatment was attempted after 4 weeks; in case of stable disease (SD), a second course was given after prestimulation with interleukin 2 and followed by granulocyte macrophage colony-stimulating factor s.c. A total of 16 heavily pretreated patients received one to four BiMAb courses [21].
  • The retreatment rate with single stones using the Dornier HM3 and the Medstone STS devices was 5% and 4%, respectively, in the upper ureter, 13% and 12%, respectively, in the mid ureter, and 0% and 5%, respectively, in the lower ureter [22].
  • The lower extremity skin and nerve abnormalities improved after retreatment with prednisone [23].
  • Heretofore, the substantial toxicity of high-dose chemotherapy (up to 20% mortality in some early trials) has largely precluded the consideration of timely retreatment; however, the risk appears to have been reduced through the use of hematopoietic growth factors and peripheral blood progenitor cells [24].

Associations of Retreatment with chemical compounds

  • The likelihood of significant QTc prolongation (by more than 25% or a QTc of 0.55 s1/2 or more) was greater after halofantrine as retreatment following mefloquine failure than as primary treatment (7/10 vs 18/51; relative risk 2.0 [95% Cl 1.1-3.4], p = 0.04) [25].
  • Spectinomycin hydrochloride is indicated for uncomplicated anogenital gonococcal infections in men and women who cannot receive penicillin or probenecid, and is the drug of choice for the retreatment of patients with uncomplicated anogenital gonococcal infection who have not responded to other antibiotics [26].
  • These data indicate that the lung will be sensitive to retreatment with radiation when a full tolerance dose of cyclophosphamide precedes radiation [27].
  • Lamivudine withdrawal led to reappearance of wild-type HBV species, but retreatment led to more rapid reappearance of the mutant virus [28].
  • Recurrence of pain responded to retreatment with 153Sm-EDTMP in five of nine patients [29].

Gene context of Retreatment

  • Cell surface levels of IFNAR-1 decreased and Stat1 levels increased after IFN-beta treatment, and retreatment with IFN resulted in an attenuated induction of Mx protein expression [30].
  • To address the second aim, DF/df and df/df animals treated with PRL for 30 d starting at 12 d of age were subjected to PRL withdrawal (15 d of saline vehicle treatment), followed by PRL retreatment [31].
  • METHODS: Sequential arthroscopic biopsy samples were taken before and 24 hours after MP administration (10 patients) and at the time of RA flare (2 patients) and after retreatment with MP (1 patient) [32].
  • Following relapse, 4 of 6 patients responded to retreatment with the identical IFN alpha/IL-2 protocol [33].
  • Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group [34].

Analytical, diagnostic and therapeutic context of Retreatment

  • Clone sequence analysis of the RT domains of patients undergoing retreatment with famciclovir and/or lamivudine showed the selection of a preexisting drug-resistant mutant in one case and indicated that sequential antiviral therapy may allow the rapid selection of resistant strains [35].
  • PRK retreatments after regressed myopic LASIK [36].
  • OBJECTIVE: The purpose of the study was to evaluate the results of retreatment for low myopia after primary photorefractive keratectomy (PRK) [37].
  • We present two CD patients (one adult and one child) with a history of anaphylactic/anaphylactoid reactions to retreatment with infliximab who subsequently underwent successful desensitization and therapeutic infusion using parenteral dose escalation in an intensive care unit setting [38].
  • It is concluded that 123I-MIBG heart scintigraphy, which is able to identify cardiac adrenergic neurone abnormalities in the follow-up period after cancer therapy, may help to identify relapsed patients who are at increased risk of developing cardiotoxicity during retreatment with cardiotoxic therapy modalities [39].


  1. Letter: Retreatment with chloroquine in porphyria cutanea tarda. Kowertz, M.J. JAMA (1975) [Pubmed]
  2. Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C. Chemello, L., Cavalletto, L., Donada, C., Bonetti, P., Casarin, P., Urban, F., Bernardinello, E., Pontisso, P., Alberti, A. Gastroenterology (1997) [Pubmed]
  3. Relapse of Candida parapsilosis endocarditis after long-term suppression with flucytosin: retreatment with valve replacement and ketoconazole. Samelson, L.E., Lerner, S.A., Resnekov, L., Anagnostopoulos, C. Ann. Intern. Med. (1980) [Pubmed]
  4. Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Kraut, E.H., Grever, M.R., Bouroncle, B.A. Blood (1994) [Pubmed]
  5. Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus interferon. The Consensus Interferon Study Group. Heathcote, E.J., James, S., Mullen, K.D., Hauser, S.C., Rosenblate, H., Albert, D.G. Hepatology (1999) [Pubmed]
  6. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. Espinal, M.A., Kim, S.J., Suarez, P.G., Kam, K.M., Khomenko, A.G., Migliori, G.B., Baéz, J., Kochi, A., Dye, C., Raviglione, M.C. JAMA (2000) [Pubmed]
  7. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients. Taliani, G., Gemignani, G., Ferrari, C., Aceti, A., Bartolozzi, D., Blanc, P.L., Capanni, M., Esperti, F., Forte, P., Guadagnino, V., Mari, T., Marino, N., Milani, S., Pasquazzi, C., Rosina, F., Tacconi, D., Toti, M., Zignego, A.L., Messerini, L., Stroffolini, T. Gastroenterology (2006) [Pubmed]
  8. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Sulo, J., Chimpeni, P., Hatcher, J., Kublin, J.G., Plowe, C.V., Molyneux, M.E., Marsh, K., Taylor, T.E., Watkins, W.M., Winstanley, P.A. Lancet (2002) [Pubmed]
  9. Effects of artemisinin derivatives on malaria transmissibility. Price, R.N., Nosten, F., Luxemburger, C., ter Kuile, F.O., Paiphun, L., Chongsuphajaisiddhi, T., White, N.J. Lancet (1996) [Pubmed]
  10. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Dienstag, J.L., Cianciara, J., Karayalcin, S., Kowdley, K.V., Willems, B., Plisek, S., Woessner, M., Gardner, S., Schiff, E. Hepatology (2003) [Pubmed]
  11. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). Cammà, C., Giunta, M., Chemello, L., Alberti, A., Toyoda, H., Trepo, C., Marcellin, P., Zahm, F., Schalm, S., Craxì, A. Hepatology (1999) [Pubmed]
  12. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Davis, G.L. Semin. Liver Dis. (1999) [Pubmed]
  13. Azathioprine toxicity in neuromuscular disease. Kissel, J.T., Levy, R.J., Mendell, J.R., Griggs, R.C. Neurology (1986) [Pubmed]
  14. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. Teuber, G., Pascu, M., Berg, T., Lafrenz, M., Pausch, J., Kullmann, F., Ramadori, G., Arnold, R., Weidenbach, H., Musch, E., Junge, U., Wiedmann, K.H., Herrmann, E., Zankel, M., Zeuzem, S. J. Hepatol. (2003) [Pubmed]
  15. Retreatment for significant regression after excimer laser photorefractive keratectomy. A prospective, randomized, masked trial. Gartry, D.S., Larkin, D.F., Hill, A.R., Ficker, L.A., Steele, A.D. Ophthalmology (1998) [Pubmed]
  16. Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo. Stephens, T.C., Adams, K., Peacock, J.H. Br. J. Cancer (1986) [Pubmed]
  17. Intramuscular administration of iron during long-term chelation therapy with 2,3-dimercaptosuccinic acid in a man with severe lead poisoning. Haust, H.L., Inwood, M., Spence, J.D., Poon, H.C., Peter, F. Clin. Biochem. (1989) [Pubmed]
  18. Calcium hydroxide in endodontic retreatment after two nonsurgical and two surgical failures: report of a case. Fava, L.R. International endodontic journal. (2001) [Pubmed]
  19. Bone densitometry as an adjunct to GnRH agonist therapy. Cann, C.E. The Journal of reproductive medicine. (1998) [Pubmed]
  20. Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Sadowitz, P.D., Smith, S.D., Shuster, J., Wharam, M.D., Buchanan, G.R., Rivera, G.K. Blood (1993) [Pubmed]
  21. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Hartmann, F., Renner, C., Jung, W., da Costa, L., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., Pfreundschuh, M. Clin. Cancer Res. (2001) [Pubmed]
  22. Extracorporeal shock wave lithotripsy for ureteral calculi. Cass, A.S. J. Urol. (1992) [Pubmed]
  23. Lower extremity peripheral neuropathy and ischemic ulcers associated with giant cell arteritis. Bridges, A.J., Porter, J., England, D. J. Rheumatol. (1989) [Pubmed]
  24. High-intensity chemotherapy with hematopoietic support in breast cancer. Crown, J., Vahdat, L., Fennelly, D., Francis, P., Wasserheit, C., Hudis, C., Kritz, A., Schneider, J., Hamilton, N., Gilewski, T. Ann. N. Y. Acad. Sci. (1993) [Pubmed]
  25. Cardiac effects of antimalarial treatment with halofantrine. Nosten, F., ter Kuile, F.O., Luxemburger, C., Woodrow, C., Kyle, D.E., Chongsuphajaisiddhi, T., White, N.J. Lancet (1993) [Pubmed]
  26. Drugs five years later. Spectinomycin. McCormack, W.M., Finland, M. Ann. Intern. Med. (1976) [Pubmed]
  27. Residual damage in mouse lungs at long intervals after cyclophosphamide treatment. Travis, E.L., Bucci, L., Fang, M.Z. Cancer Res. (1990) [Pubmed]
  28. Long-term therapy of chronic hepatitis B with lamivudine. Lau, D.T., Khokhar, M.F., Doo, E., Ghany, M.G., Herion, D., Park, Y., Kleiner, D.E., Schmid, P., Condreay, L.D., Gauthier, J., Kuhns, M.C., Liang, T.J., Hoofnagle, J.H. Hepatology (2000) [Pubmed]
  29. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. Turner, J.H., Claringbold, P.G., Hetherington, E.L., Sorby, P., Martindale, A.A. J. Clin. Oncol. (1989) [Pubmed]
  30. Mechanisms for regulation of cellular responsiveness to human IFN-beta1a. Dupont, S.A., Goelz, S., Goyal, J., Green, M. J. Interferon Cytokine Res. (2002) [Pubmed]
  31. Prolactin replacement must be continuous and initiated prior to 21 d of age to maintain hypothalamic dopaminergic neurons in hypopituitary mice. Phelps, C.J., Romero, M.I., Hurley, D.L. Endocrine (2003) [Pubmed]
  32. Effects of pulse methylprednisolone on cell adhesion molecules in the synovial membrane in rheumatoid arthritis. Reduced E-selectin and intercellular adhesion molecule 1 expression. Youssef, P.P., Triantafillou, S., Parker, A., Coleman, M., Roberts-Thomson, P.J., Ahern, M.J., Smith, M.D. Arthritis Rheum. (1996) [Pubmed]
  33. Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Keilholz, U., Scheibenbogen, C., Stoelben, E., Saeger, H.D., Hunstein, W. Eur. J. Cancer (1994) [Pubmed]
  34. Retreatment with alteplase for early signs of reocclusion after thrombolysis. The European Cooperative Study Group. Simoons, M.L., Arnout, J., van den Brand, M., Nÿssen, K., Verstraete, M. Am. J. Cardiol. (1993) [Pubmed]
  35. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. Seignères, B., Pichoud, C., Ahmed, S.S., Hantz, O., Trépo, C., Zoulim, F. J. Infect. Dis. (2000) [Pubmed]
  36. PRK retreatments after regressed myopic LASIK. Yavitz, E. Ophthalmology (2002) [Pubmed]
  37. Retreatment after photorefractive keratectomy for low myopia. Rozsíval, P., Feuermannová, A. Ophthalmology (1998) [Pubmed]
  38. Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Puchner, T.C., Kugathasan, S., Kelly, K.J., Binion, D.G. Inflamm. Bowel Dis. (2001) [Pubmed]
  39. Iodine-123 metaiodobenzylguanidine in the assessment of late cardiac effects from cancer therapy. Valdés Olmos, R.A., ten Bokkel Huinink, W.W., Dewit, L.G., Hoefnagel, C.A., Liem, I.H., van Tinteren, H. European journal of nuclear medicine. (1996) [Pubmed]
WikiGenes - Universities